{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-26-000022","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.987969+00:00","generated_at":"2026-05-15T08:21:17.884252+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aquestive completes FDA Type A meeting for Anaphylm; NDA resubmission reaffirmed for Q3 2026","bullets":["Received FDA clarifying feedback on PK and human factor study designs for Anaphylm.","FDA aligned on labeling to manage potential chewing of film, avoiding additional clinical data.","Container closure changes acknowledged; will be tested in upcoming HF study.","Final FDA meeting minutes expected by early May 2026.","Regulatory submissions for Canada and EU continue."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-26-000022","json":"https://secwatch.observer/filing/0001398733-26-000022.json","markdown":"https://secwatch.observer/filing/0001398733-26-000022.md","text":"https://secwatch.observer/filing/0001398733-26-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000022/0001398733-26-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000022/aqst-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:21:17.884252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}